# Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers

> **NCT01926626** · PHASE2 · COMPLETED · sponsor: **Jed E. Rose** · enrollment: 76 (actual)

## Conditions studied

- Nicotine Dependence

## Interventions

- **DRUG:** Nicotine Patch
- **DRUG:** Moclobemide

## Key facts

- **NCT ID:** NCT01926626
- **Lead sponsor:** Jed E. Rose
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2014-07
- **Final completion:** 2014-10
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2017-08-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01926626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01926626, "Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01926626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*